von Eynatten M, Liu D, Bluemm A, Schuster T, Baumann M, Lutz J, Heemann U, Dugi K A, Nawroth P P, Bierhaus A, Humpert P M
Department of Nephrology, Technische Universitaet Muenchen, Munich, Germany.
Clin Endocrinol (Oxf). 2009 Jul;71(1):27-32. doi: 10.1111/j.1365-2265.2008.03412.x.
Multimeric high molecular weight (HMW) forms of adiponectin were previously shown to be inversely associated with the extent of atherosclerosis in males and are down-regulated in patients with the metabolic syndrome and type 2 diabetes. In this study, potential influences of atorvastatin therapy on adiponectin multimer distribution were studied in patients with type 2 diabetes.
DESIGN, PATIENTS AND MEASUREMENTS: The effect of 40 mg atorvastatin on HMW, medium molecular weight (MMW), and low molecular weight (LMW) isoforms of adiponectin were investigated in 75 patients (23 females; 52 males) with type 2 diabetes in an 8-week-long, placebo-controlled and randomized study. Adiponectin multimeric isoforms were detected by Western blot analysis.
After atorvastatin therapy the median serum concentration of HMW adiponectin increased significantly by 42.3% (1.68 vs. 2.39 microg/ml; P < 0.001), while concentrations of MMW adiponectin and LMW adiponectin significantly decreased by 20.8% and 23.2%, respectively (MMW: 3.31 vs. 2.62 microg/ml, P = 0.047; LMW: 0.56 vs. 0.43 microg/ml, P = 0.033). Median total adiponectin levels were not significantly altered by atorvastatin treatment (6.0 vs. 6.2 microg/ml, P = 0.898). Consequently, the HMW: total-adiponectin ratio significantly increased by 25.0% (0.40 vs. 0.50; P = 0.013).
Atorvastatin therapy is associated with significant changes in adiponectin multimer distribution in patients with type 2 diabetes. Since total adiponectin levels were not affected by intervention, atorvastatin may shift adiponectin size towards the HMW form.
先前研究表明，多聚体形式的高分子量（HMW）脂联素与男性动脉粥样硬化程度呈负相关，且在代谢综合征和2型糖尿病患者中表达下调。本研究旨在探讨阿托伐他汀治疗对2型糖尿病患者脂联素多聚体分布的潜在影响。
设计、患者与测量：在一项为期8周的安慰剂对照随机研究中，对75例2型糖尿病患者（23例女性；52例男性）进行研究，观察40 mg阿托伐他汀对脂联素HMW、中分子量（MMW）和低分子量（LMW）亚型的影响。采用蛋白质印迹分析检测脂联素多聚体亚型。
阿托伐他汀治疗后，HMW脂联素的血清中位数浓度显著升高42.3%（1.68 vs. 2.39 μg/ml；P < 0.001），而MMW脂联素和LMW脂联素的浓度分别显著降低20.8%和23.2%（MMW：3.31 vs. 2.62 μg/ml，P = 0.047；LMW：0.56 vs. 0.43 μg/ml，P = 0.033）。阿托伐他汀治疗未显著改变脂联素总水平的中位数（6.0 vs. 6.2 μg/ml，P = 0.898）。因此，HMW与总脂联素的比值显著升高25.0%（0.40 vs. 0.50；P = 0.013）。
阿托伐他汀治疗与2型糖尿病患者脂联素多聚体分布的显著变化有关。由于总脂联素水平不受干预影响，阿托伐他汀可能使脂联素大小向HMW形式转变。
